These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 6678853)

  • 1. Survival and cell cycle kinetics responses of Chinese hamster ovary cells, and clones of human adenocarcinoma of the stomach and astrocytoma to diaziquone (AZQ) in vitro.
    Barranco SC; Schechter GA; Boerwinkle WR; Howell KA; Rubin NH
    Invest New Drugs; 1983; 1(1):11-9. PubMed ID: 6678853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas.
    Greenberg HS; Ensminger WD; Layton PB; Gebarski S; Meyer M; Chaffee B; Bender JF; Grillo-Lopez AJ
    Cancer Treat Rep; 1986 Mar; 70(3):353-7. PubMed ID: 3006913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of diaziquone in untreated advanced gastric carcinoma. A Southwest Oncology Group Study.
    Pugh RP; Fleming T; Guy JT; Weick JK; Ward JH
    Am J Clin Oncol; 1989 Feb; 12(1):11-3. PubMed ID: 2912017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of 2,5,-diaziridinyl 3,6-bis (carboethoxy amino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors.
    Feun LG; Yung WK; Leavens ME; Burgess MA; Obbens EA; Bedikian AY; Savaraj N; Stewart DJ; Benjamin RS; Fields WS
    J Neurooncol; 1984; 2(1):13-7. PubMed ID: 6088722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of DNA strand breaks and cross-links by 2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone in Chinese hamster ovary cells.
    King CL; Hittelman WN; Loo TL
    Cancer Res; 1984 Dec; 44(12 Pt 1):5634-7. PubMed ID: 6498824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive phase II evaluation of aziridinylbenzoquinone (AZQ, diaziquone) in recurrent human primary brain tumors.
    Eagan RT; Dinapoli RP; Cascino TL; Scheithauer B; O'Neill BP; O'Fallon JR
    J Neurooncol; 1987; 5(4):309-14. PubMed ID: 3440875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II clinical evaluation of AZQ in adenocarcinoma of the lung.
    Decker DA; Samson MK; Haas CD; Baker LH
    Am J Clin Oncol; 1984 Aug; 7(4):353-5. PubMed ID: 6741865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the L isomer (+)-1,2-bis(3,5-dioxopiperazine-1-yl)propane on cell survival and cell cycle progression of cultured mammalian cells.
    Traganos F; Darzynkiewicz Z; Melamed MR
    Cancer Res; 1981 Nov; 41(11 Pt 1):4566-76. PubMed ID: 6171341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II clinical trial of diaziquone in the treatment of patients with recurrent endometrial carcinoma. A Gynecologic Oncology Group study.
    Slayton RE; Blessing JA; DiSaia PJ; Phillips G
    Am J Clin Oncol; 1988 Dec; 11(6):612-3. PubMed ID: 3055931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II clinical evaluation of AZQ in renal cell carcinoma.
    Decker DA; Kish J; Al-Sarraf M; Goldfarb S
    Am J Clin Oncol; 1986 Apr; 9(2):126-8. PubMed ID: 3717078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell killing and kinetic effects of diglycolaldehyde on dividing and nondividing mammalian cells in vitro.
    Barranco SC; Flournoy DR; Bolton WE; Oka MS
    J Natl Cancer Inst; 1978 Nov; 61(5):1307-10. PubMed ID: 280715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell killing, kinetics, and recovery responses induced by 1,2:5,6-dianhydrogalactitol in dividing and nondividiing cells in vitro.
    Barranco SC; Flournoy DR
    J Natl Cancer Inst; 1977 Mar; 58(3):657-63. PubMed ID: 839561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of aziridinylbenzoquinone (AZQ: NSC-182986) in the treatment of malignant gliomas recurrent after radiation. Preliminary report.
    Decker DA; Al Sarraf M; Kresge C; Austin D; Wilner HI
    J Neurooncol; 1985; 3(1):19-21. PubMed ID: 2987424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of diaziquone.
    Frytak S; Eagan RT; Ames MM; Creagan ET; Nichols WC
    Cancer Treat Rep; 1984; 68(7-8):975-8. PubMed ID: 6744349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response variability of human brain tumors to AZQ in tissue culture.
    Kornblith PL; Rosa L; Bona JD; Edwards JA; Matuzic N; Hirschfeld A; Hawkins C
    J Neurooncol; 1986; 4(1):49-54. PubMed ID: 3746385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular pharmacology in murine and human leukemic cell lines of diaziquone (NSC 182986).
    Egorin MJ; Fox BM; Spiegel JF; Gutierrez PL; Friedman RD; Bachur NR
    Cancer Res; 1985 Mar; 45(3):992-9. PubMed ID: 3971389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lethality, DNA alkylation, and cell cycle effects of adozelesin (U-73975) on rodent and human cells.
    Bhuyan BK; Smith KS; Adams EG; Petzold GL; McGovren JP
    Cancer Res; 1992 Oct; 52(20):5687-92. PubMed ID: 1394193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial and pharmacokinetics of aziridinylbenzoquinone (NSC 182986) in humans.
    Schilsky RL; Kelley JA; Ihde DC; Howser DM; Cordes RS; Young RC
    Cancer Res; 1982 Apr; 42(4):1582-6. PubMed ID: 7060028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced cell killing through the use of cell kinetics-directed treatment schedules for two-drug combinations in vitro.
    Barranco SC; May JT; Boerwinkle W; Nichols S; Hokanson KM; Schumann J; Göhde W; Bryant J; Guseman LF
    Cancer Res; 1982 Jul; 42(7):2894-8. PubMed ID: 6177399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sister chromatid exchange induction by diaziquone in human and mouse lymphocytes following both in vivo and in vitro exposures.
    Kligerman AD; Erexson GL; Bryant MF
    Cancer Res; 1988 Jan; 48(1):27-31. PubMed ID: 3334997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.